Cytokeratin 13 Antibody (A-5): sc-376901

Cytokeratin 13 Antibody (A-5) is a mouse monoclonal IgG2b kappa light chain antibody that detects Cytokeratin 13 (CK13) of human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and enzyme-linked immunosorbent assay (ELISA). Anti-CK13 antibody (A-5) is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. CK13 is a member of the intermediate filament protein family, specifically forming a heterotetramer with cytokeratin 4, and is primarily located in the cytoskeletal region of non-keratinized stratified squamous epithelia. This localization contributes to the structural integrity and mechanical resilience of epithelial cells, particularly in tissues that undergo significant stress or abrasion. CK13 serves as a marker for tissue differentiation in squamous cell carcinomas and aids in characterizing malignant tumors. Mutations in the KRT13 gene can lead to white sponge nevus of Cannon, a rare genetic disorder characterized by soft, white, spongy lesions in the oral mucosa, highlighting CK13′s clinical significance in both normal physiology and disease states.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Cytokeratin 13 Antibody (A-5) References:

1. Identification of two novel mutations in keratin 13 as the cause of white sponge naevus.  |  Rugg, E., et al. 1999. Oral Dis. 5: 321-4. PMID: 10561721
2. A novel mutation in the keratin 13 gene causing oral white sponge nevus.  |  Terrinoni, A., et al. 2001. J Dent Res. 80: 919-23. PMID: 11379896
3. A novel mutation in the keratin 4 gene causing white sponge naevus.  |  Chao, SC., et al. 2003. Br J Dermatol. 148: 1125-8. PMID: 12828738
4. Down-regulation of keratin 4 and keratin 13 expression in oral squamous cell carcinoma and epithelial dysplasia: a clue for histopathogenesis.  |  Sakamoto, K., et al. 2011. Histopathology. 58: 531-42. PMID: 21371075
5. Emergence of keratin 17 vs. loss of keratin 13: their reciprocal immunohistochemical profiles in oral carcinoma in situ.  |  Mikami, T., et al. 2011. Oral Oncol. 47: 497-503. PMID: 21489858
6. Keratin 13 is a more specific marker of conjunctival epithelium than keratin 19.  |  Ramirez-Miranda, A., et al. 2011. Mol Vis. 17: 1652-61. PMID: 21738394
7. Keratin 13 immunostaining in corneal impression cytology for the diagnosis of limbal stem cell deficiency.  |  Poli, M., et al. 2011. Invest Ophthalmol Vis Sci. 52: 9411-5. PMID: 22064992
8. Sequence of a human keratin 13 specific cDNA encompassing coil 1B through the 3' end.  |  Schulz, P., et al. 1989. Biochem Biophys Res Commun. 162: 1522-7. PMID: 2475110
9. Epigenetic alterations of the keratin 13 gene in oral squamous cell carcinoma.  |  Naganuma, K., et al. 2014. BMC Cancer. 14: 988. PMID: 25527207
10. Keratin 13 Is Enriched in Prostate Tubule-Initiating Cells and May Identify Primary Prostate Tumors that Metastasize to the Bone.  |  Liu, S., et al. 2016. PLoS One. 11: e0163232. PMID: 27711225
11. Keratin 13 gene is epigenetically suppressed during transforming growth factor-β1-induced epithelial-mesenchymal transition in a human keratinocyte cell line.  |  Hatta, M., et al. 2018. Biochem Biophys Res Commun. 496: 381-386. PMID: 29326042
12. Keratin 13 point mutation underlies the hereditary mucosal epithelial disorder white sponge nevus.  |  Richard, G., et al. 1995. Nat Genet. 11: 453-5. PMID: 7493031

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-Cytokeratin 13 Antibody (A-5) has 0 citations in a variety of scientific publications.

Primary antibodies like Anti-Cytokeratin 13 Antibody (A-5) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

Cytokeratin 13 Antibody (A-5) Specifications

Alternate Product Name: KRT13

Product Clone Name: A-5

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG_2b kappa light chain

Amino Acids: 405-439

Epitope Target: Cytokeratin 13

Epitope Species: human

Product Reactivity/Detection: Cytokeratin 13

Species Reactivity/Detection: human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, IHC(P), ELISA

Vialing Information: Each vial contains 200 µg IgG_2b kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 0 citations in various scientific publications

Available Conjugates/Forms for Cytokeratin 13 Antibody (A-5): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, P: Blocking Peptide, PE: Phycoerythrin